Prothena (PRTA)
(Delayed Data from NSDQ)
$21.61 USD
-0.05 (-0.23%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $21.61 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Prothena Corporation plc [PRTA]
Reports for Purchase
Showing records 41 - 60 ( 340 total )
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Subcutaneous PRX012 Aims for Better Efficacy and Superior Safety Profile; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Key Takeaways from Prothena?s AD Pipeline Updates at AAIC Amsterdam
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
PRX012-Neighbors? Envy, Owner?s Pride; Reit Buy and Raising PT to $90
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
PRX012?s Binding Profile Might Predict Efficacy - Takeaways from AD/PD 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
NfL Might be the Best Predictor of Motor Progression in PD-Takeaways from AD/PD 2023 Gothenburg
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Tau368, An Alternative CSF Biomarker for AD Pathology-Takeaways from AD/PD 2023 Gothenburg
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Expectations for the Phase 1 MAD Study of PRX012; Reit. Buy and $75 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
HCW 2023 Top Picks: Seize the Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Birtamimab ASH Data Comes at the Backdrop of Anti- Abeta Success?Our Takeaways From ASH 2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Learnings from the Gantenerumab Trial?Implications for Prothena
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Prothena Aims to Lead the Next-Generation AD Immunotherapy Space; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Seed for Successful PD Trial Outcome is Sown?Takeaways From the 2022 PD Therapeutic Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A